A US Food and Drug Administration (FDA) advisory panel has endorsed a booster shot of the Pfizer-BioNTech Covid-19 vaccine six months after full inoculation in people above 65 years and for individuals at high risk for severe disease.

The decision late Friday came after members of the FDA's Vaccines and Related Biological Products Advisory Committee voted against advising the agency to approve boosters for anyone 16 and older after hours of debate, reports Xinhua news agency.